Immunocompromised children age 6-71 months and immunogenicity to inactivated enterovirus 71 vaccine Immunocompromised hosts, immunocompromised patients, oncology, rheumatology, inactivated vaccine
Conditions
Interventions
Inactivated enterovirus type 71 (human diploid cell) vaccine 0.5 ml Intramuscular route doses at day 0,28 The vaccine was prepared from the C4 subgenogroup of EV-A71 C4a Fy23 strain, cultured in a hum
Immunocompromised hosts,Healthy
Sponsors
Faculty of medicine Ramathibodi hospital, Mahidol university
Eligibility
Sex/Gender
All
Age
6 Months to 71 Months
Inclusion criteria
Inclusion criteria: 1. Participants aged 6-71 months 2. Being an immunocompromised host, such as patients with cancer who are undergoing chemotherapy, patients with rheumatological disease and receiving immunomodulating or immunosuppressive treatment (51 cases) or healthy (25 cases) 3. Being followed at Ramathibodi Hospital, Chakri Naruebodindra Medical Institute, and Phramongkutklao Hospital 4. No history of receiving the inactivated EV71 vaccine 5. Provide informed consent 6. Parents or LARs understand the Thai language
Exclusion criteria
Exclusion criteria: 1. Having a history of severe allergic reaction to vaccine or vaccine component 2. Having a fever > 38.3 C on a day of immunization 3. Receiving induction chemotherapy 4. Recipient of stem cell transplant within 6 months 5. Recipient of solid organ transplant within 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| seropositivity rate prior and at 1 month after 2nd dose of vaccine anti-EV71 neutralizing antibody level | — |
Secondary
| Measure | Time frame |
|---|---|
| seroprotective rate prior and at 1 month after 2nd dose of vaccine anti-EV71 neutralizing antibody level | — |
Countries
Thailand
Contacts
Public ContactPornnatcha Asawakanjanakij
Department of Pediatrics,Faculty of Medicine Ramathibodi Hospital
Outcome results
None listed